Docoh
Loading...

CMPI Checkmate Pharmaceuticals

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Friday
14 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Friday's session, 445 companies made new 52-week lows.
Checkmate Pharmaceuticals Announces Initiation Of Patient Dosing In Phase 2 Multi-Indication Trial Using Vidutolimod
20 Dec 21
Biotech, News, FDA, General
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat
12 Health Care Stocks Moving In Wednesday's After-Market Session
15 Dec 21
Movers
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
12 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Checkmate Pharmaceuticals Q3 EPS $(0.69) Up From $(0.84) YoY
12 Nov 21
Earnings, News
Checkmate Pharmaceuticals (NASDAQ:CMPI) reported quarterly losses of $(0.69) per share. This is a 17.86 percent increase over losses of $(0.84) per share from the same period last year.
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
8 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories, General
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
24 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.

Press releases

From Benzinga Pro
Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
3 Jan 22
News, Press Releases
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness
Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
15 Nov 21
News, Press Releases
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness
Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
12 Nov 21
Earnings, Press Releases
Alan Fuhrman appointed interim President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing Clinical data readouts anticipated in 2022 CAMBRIDGE,
Checkmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
12 Nov 21
Health Care, Press Releases
Vidutolimod in combination with pembrolizumab demonstrated promising clinical activity in patients with PD-1 blockade-refractory melanoma with an ORR of 23.5% per RECIST v1.1 Vidutolimod also demonstrated monotherapy
Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference
11 Nov 21
News, Press Releases
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness
Checkmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
1 Nov 21
News, Press Releases
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing proprietary technology to harness the power
Checkmate Pharmaceuticals Announces CEO Transition
27 Oct 21
News, Management, Press Releases
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness